NewsBenzingaセレクタール・バイオサイエンシズ、イオポフォシン I 131で治療されたびまん性大細胞型B細胞リンパ腫の多治療歴患者における持続的完全奏効を示す症例研究の結果を報告 セレクタール・バイオサイエンシズ、イオポフォシン I 131で治療されたびまん性大細胞型B細胞リンパ腫の多治療歴患者における持続的完全奏効を示す症例研究の結果を報告 Benzinga 2026.10.27 11:16 (GMT+0) Open on Benzinga Other news Arthur Hayes: Bullish on ETH, ZEC, NEAR and VVV, Has Built Small- and Mid-Sized Positions Huang's Nvidia Return Odds Rebound to 11% on Kalshi Hackers Spread Crypto-Stealing Trojan via Fake GTA 6 PC Download Links Invesco's Stablecoin Reserve Fund Goes Live on Ethereum 7 Major US Banks Disclose XRP ETF Holdings in SEC Filings, Totaling About $29.4M Anthropic Requires Employees to Set Written Plans 30 Days in Advance to Sell Shares, to Prevent Insider Trading
Anthropic Requires Employees to Set Written Plans 30 Days in Advance to Sell Shares, to Prevent Insider Trading